#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials
Breakpoints
00:00
Antiretroviral Therapy
A majority of patients are diagnosed with HIV still relatively late in the disease course as defined by presenting with a very low CD4 cell count. We at this point, standard of care, we agree that if a patient is HIV positive, we're going to start antiretroviral therapy as soon as possible. Now here's a part that they presented at ID Week 2022. They actually extended this study through six-year follow-up, which ended in December of 2021. The primary composite endpoint for that original design of the trial was either serious AIDS defined as AIDS related illness or death.
Transcript
Play full episode
